Monday, July 15, 2013
Rxi Pharmaceuticals Corp., of Westborough, Mass., reported positive results of a Phase I study of RXI-109, an sd-rxRNA, for abnormal dermal scars.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.